The Vita Coco Company, Inc.'s SEC filings document financial results, operating updates, governance matters, and public-company disclosures for its beverage brand portfolio. Form 8-K reports include quarterly and annual results, guidance updates, Regulation FD disclosures, and other material events related to the company’s coconut water and better-for-you beverage operations.
Proxy materials describe annual meeting proposals, board structure, committee assignments, executive compensation, equity awards, and stockholder voting matters. Additional 8-K filings record director appointments, board retirements, officer roles, compensation arrangements, tariff-related disclosures, and the company’s capital-market reporting obligations as a Nasdaq-listed Delaware corporation.
Vita Coco Company, Inc. (COCO) notice records a proposed sale under Rule 144 and recent 10b5-1 transactions by an insider. The filer plans to sell 20,000 common shares through Morgan Stanley Smith Barney at an aggregate market value of $799,600, representing securities outstanding of 56,822,981 shares, with an approximate sale date of 09/17/2025.
The securities were acquired on 09/17/2025 by exercise of stock options and paid in cash. The filing also discloses two prior 10b5-1 sales this year: 10,000 shares on 07/07/2025 for $380,178 and 10,000 shares on 09/12/2025 for $400,019.
Form 144 notice for Vita Coco Company, Inc. (COCO) shows a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,999,000, with an approximate sale date of 09/17/2025. The shares were acquired as founders shares on 09/10/2010. The filing also reports two recent 10b5-1 sales by the MICHAEL KIRBAN 2010 TRUST: 20,000 shares sold on 09/11/2025 for $780,898 and 30,000 shares sold on 09/09/2025 for $1,174,821. There are 56,822,981 shares outstanding reported on the form. The filer affirms compliance representations required under Rule 144 and 10b5-1 trading-plan attestations.
Vita Coco Company, Inc. (COCO) filing a Form 144 notifies the proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 09/17/2025 with an aggregate market value of $399,800.00. The shares were acquired and paid for on 09/17/2025 by exercise of stock options, with payment in cash. The filer also reported three prior 10b5-1 sales this year totaling 30,000 shares on 06/18/2025, 07/01/2025 and 09/12/2025, with gross proceeds shown for each sale.
Vita Coco Company, Inc. (COCO) filing of Form 144 reports a proposed sale of 21,700 common shares by an insider acquired as stock compensation on 07/12/2016. The filing lists the broker as The Charles Schwab Corporation and shows an aggregate market value of $1,068,399.00 for the proposed sale with an approximate sale date of 09/17/2025 on NASDAQ. The filer also disclosed two prior sales by the same person totaling 7,800 shares during July and August 2025 that generated combined gross proceeds of $285,088.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported transactions dated 09/12/2025 on Form 4. He exercised a stock option to acquire 10,000 shares at an exercise price of $10.178 per share and simultaneously sold 10,000 shares under a Rule 10b5-1 plan at a weighted average price of $40.002 per share. After these transactions his beneficial ownership is reported as 84,328 shares. The filing itemizes multiple outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules; some options are fully vested and exercisable. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/16/2025.
Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported sales of common stock on 09/12/2025 executed under a Rule 10b5-1 trading plan. The filing shows four sell transactions of 5,000 shares each at weighted-average prices around $40.01, reducing the reporting person's direct beneficial ownership to 352,062 shares. Separate lines show indirect holdings of 286,131 shares held by each of three family trusts and 61,200 shares held by a spouse. The form also discloses multiple fully vested and outstanding non-qualified stock options with various exercise prices and vesting schedules, including options exercisable for 579,670 shares and others vesting through 2035.
Jane Prior, Chief Marketing Officer of Vita Coco Company, Inc. (COCO), reported transactions dated 09/12/2025. She acquired 10,000 shares of common stock by exercising non-qualified stock options at an exercise price of $10.178 per share and simultaneously sold 10,000 shares pursuant to a Rule 10b5-1 trading plan for a weighted average price of $40.002 per share (sales ranged $40.00–$40.03). After these transactions her beneficial ownership is reported as 123,666 shares. The filing lists outstanding non-qualified stock options covering additional shares (totaling ~155,739 underlying shares across multiple grants) with various vesting schedules and exercise prices, several of which are fully vested and exercisable.
Vita Coco Company director Liran Ira reported two securities dispositions on 09/12/2025. The filings show sales of 20,000 and 40,000 shares of common stock executed under a Rule 10b5-1 trading plan, with weighted-average prices reported near $40.00 per share. After the transactions the reporting person is shown as beneficially owning 598,341 shares directly and 742,579 shares indirectly (held by the Ira Liran 2012 Family Trust). The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Jonathan Burth, Chief Operating Officer of Vita Coco Company, Inc. (COCO), reported a sale of 10,000 shares of common stock on 09/12/2025 at a weighted average price of $40.003 under a Rule 10b5-1 trading plan, leaving him with 76,127 shares beneficially owned following the transaction. The Form 4 also discloses multiple outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules and exercisability dates. The filing was signed by Alison Klein, Attorney-in-Fact, on 09/16/2025.
Vita Coco Company, Inc. (COCO) filing a Form 144 notifies the proposed sale of 3,000 common shares to be sold through Morgan Stanley Smith Barney on 09/16/2025 on NASDAQ. The shares were acquired the same day by exercise of stock options and paid for in cash.
The filing also discloses multiple recent 10b5-1 sales by Corey Baker totaling 7,000 shares across nine trading dates from 09/05/2025 to 09/15/2025 with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and includes broker details and share counts but provides no additional context about ownership percentage or intent.